- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Overall survival data for Imfinzi: Stage III NSCLC
AnnouncementREG - AstraZeneca PLC - EMA approves AZ's Imfinzi for Stage III NSCLC
AnnouncementREG - AstraZeneca PLC - Farxiga gets positive result in DECLARE-TIMI 58
AnnouncementREG - AstraZeneca PLC - FDA approves AZ's Lumoxiti in hairy cell leukaemia
AnnouncementREG - AstraZeneca PLC - Tezepelumab FDA Breakthrough Therapy Designation
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca Update on Anifrolumab in SLE
AnnouncementREG - AstraZeneca PLC - EC approves Bydureon BCise device for T2 diabetes
AnnouncementREG - AstraZeneca PLC - AstraZeneca PIIIb trial update for Bevespi in COPD
AnnouncementREG - AstraZeneca PLC - AZ's Tagrisso approved in Japan for 1st-line NSCLC
AnnouncementREG - AstraZeneca PLC - AstraZeneca prices a $3bn bond issue
AnnouncementREG - AstraZeneca PLC - EMA grants OD for selumetinib in NF1
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - CHMP recommends Imfinzi for Stage III nsclc
AnnouncementREG - AstraZeneca PLC - AZN: H1 2018 Results
AnnouncementREG - AstraZeneca PLC - Atacand to be divested to Cheplapharm in Europe
AnnouncementREG - Circassia Pharma Plc AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
Announcement